Vaxart, Inc. (VXRT)
0.486
-0.01
(-2.78%)
USD |
OTCM |
Sep 18, 16:00
Vaxart Enterprise Value : 66.58M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 66.58M |
| September 17, 2026 | 69.96M |
| September 16, 2026 | 63.67M |
| September 15, 2026 | 65.12M |
| September 14, 2026 | 67.55M |
| September 11, 2026 | 66.34M |
| September 10, 2026 | 66.84M |
| September 09, 2026 | 67.16M |
| September 08, 2026 | 70.88M |
| September 04, 2026 | 68.77M |
| September 03, 2026 | 68.16M |
| September 02, 2026 | 67.67M |
| September 01, 2026 | 68.28M |
| August 31, 2026 | 72.41M |
| August 28, 2026 | 70.38M |
| August 27, 2026 | 70.78M |
| August 26, 2026 | 71.07M |
| August 25, 2026 | 70.59M |
| August 24, 2026 | 70.10M |
| August 21, 2026 | 73.62M |
| August 20, 2026 | 74.76M |
| August 19, 2026 | 69.44M |
| August 18, 2026 | 68.78M |
| August 17, 2026 | 68.52M |
| August 14, 2026 | 80.54M |
| Date | Value |
|---|---|
| August 13, 2026 | 84.55M |
| August 12, 2026 | 84.50M |
| August 11, 2026 | 83.88M |
| August 10, 2026 | 88.19M |
| August 07, 2026 | 82.24M |
| August 06, 2026 | 86.98M |
| August 05, 2026 | 91.71M |
| August 04, 2026 | 94.26M |
| August 03, 2026 | 91.84M |
| July 31, 2026 | 79.69M |
| July 30, 2026 | 76.54M |
| July 29, 2026 | 65.78M |
| July 28, 2026 | 65.61M |
| July 27, 2026 | 57.86M |
| July 24, 2026 | 68.77M |
| July 23, 2026 | 69.86M |
| July 22, 2026 | 64.64M |
| July 21, 2026 | 70.77M |
| July 20, 2026 | 69.98M |
| July 17, 2026 | 73.62M |
| July 16, 2026 | 73.59M |
| July 15, 2026 | 77.26M |
| July 14, 2026 | 82.12M |
| July 13, 2026 | 80.19M |
| July 10, 2026 | 81.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 599.19M |
| Amgen, Inc. | 251.80B |
| Anika Therapeutics, Inc. | 265.34M |
| BioCryst Pharmaceuticals, Inc. | 2.699B |
| Imunon, Inc. | 7.326M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.49M |
| Revenue (Quarterly) | 27.18M |
| Total Expenses (Quarterly) | 40.68M |
| EPS Diluted (Quarterly) | -0.0557 |
| Gross Profit Margin (Quarterly) | 97.27% |
| Profit Margin (Quarterly) | -49.64% |
| Earnings Yield | 32.72% |
| Operating Earnings Yield | 34.18% |
| Normalized Earnings Yield | 32.72 |